Literature DB >> 20217999

Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.

J Chmielewska1, M Rånby, B Wiman.   

Abstract

An improved assay method for tissue plasminogen activator (t-PA) in plasma samples is described, which allows the plasma t-PA activity to be determined within 3 hours. The method minimizes the action of possible inhibitors by immediate acidification of blood samples prior to separation of the blood cells. In almost all plasma samples variable amounts of a rapid t-PA inhibitor could be demonstrated. The inhibitor was present in plasma and seemed not to be associated with the blood cells. A quantitative method for determination of the inhibitor content in plasma was developed. In this investigation 1 unit of inhibitor is defined as the amount that neutralized 1 unit (0.06 pmol) of t-PA in 10 minutes. The content of t-PA inhibitor in plasma samples from healthy individuals was determined as 0.6 U/ml +/- 0.5 U/ml (range 0-3.2, median 0.4). In a group of patients (n = 75) with suspected disturbance of the haemostatic system, elevated levels were found (3.8 +/- 2.7, U/ml median 3.6 U/ml, range 0 - 15 U/ml). Kinetic analysis with plasma from three patients with elevated inhibitor content showed very similar rate of t-PA inhibition and assuming the formation of a 1:1 t-PA-inhibitor complex a second order rate constant of 10(7) M(-1) s(-1) was calculated. A regulatory function may be anticipated for this inhibitor, but its exact patophysiological role has still to be established.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 20217999     DOI: 10.1016/0049-3848(83)90407-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  22 in total

1.  76th General Meeting of the Japanese Society of Gastroenterology. Tokyo, Japan, March 29-31, 1990. Abstracts.

Authors: 
Journal:  Gastroenterol Jpn       Date:  1992-02

2.  Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.

Authors:  J H Jansson; B Johansson; K Boman; T K Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo.

Authors:  D E Newby; F N Witherow; R A Wright; P Bloomfield; C A Ludlam; N A Boon; K A A Fox; D J Webb
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

4.  Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man.

Authors:  S Coccheri; G Biagi; C Legnani; B Bianchini; F Grauso
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer.

Authors:  P Henriksson; M Blombäck; G Bratt; O Edhag; A Eriksson; O Vesterqvist
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

6.  Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.

Authors:  Roberto Fogari; Paola Preti; Pierangelo Lazzari; Luca Corradi; Annalisa Zoppi; Elena Fogari; Amedeo Mugellini
Journal:  Eur J Clin Pharmacol       Date:  2003-06-27       Impact factor: 2.953

7.  Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

Authors:  A Asplund-Carlson; A Hamsten; B Wiman; L A Carlson
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

8.  Job strain and plasminogen activator inhibitor-1: results from the Swedish WOLF study.

Authors:  Erica M Brostedt; Ulf de Faire; Peter Westerholm; Anders Knutsson; Lars Alfredsson
Journal:  Int Arch Occup Environ Health       Date:  2004-04-22       Impact factor: 3.015

9.  Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension.

Authors:  Carlos Zamarrón; Jorge Ricoy; Alberto Riveiro; Francisco Gude
Journal:  Lung       Date:  2008-03-11       Impact factor: 2.584

10.  Withdrawal of chronic beta-adrenoceptorblockade: effects on haemodynamics, blood lipids and haemostatic variables.

Authors:  P Smith; I Seljeflot; T Opstad
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.